Genmab A/S
CSE:GMAB
Genmab A/S
PP&E Net
Genmab A/S
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
PP&E Net
kr271m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
27%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
PP&E Net
kr129.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
22%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
PP&E Net
€92.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
48%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
PP&E Net
kr2.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
PP&E Net
kr8.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
30%
|
|
|
Saniona AB
STO:SANION
|
PP&E Net
kr7.7m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's PP&E Net?
PP&E Net
271m
DKK
Based on the financial report for Mar 31, 2025, Genmab A/S's PP&E Net amounts to 271m DKK.
What is Genmab A/S's PP&E Net growth rate?
PP&E Net CAGR 10Y
27%
Over the last year, the PP&E Net growth was -85%. The average annual PP&E Net growth rates for Genmab A/S have been -35% over the past three years , -11% over the past five years , and 27% over the past ten years .
You don't have any saved screeners yet